Invivyd
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Connecticut, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
209 Church St, New Haven, Connecticut, 0...Phone Number
(781) 819-0080Website
www.invivyd.comRevenue
$55.9 MillionStock Symbol
IVVDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on developing innovative antibody-based therapies to protect against evolving viral threats. It uses a proprietary discovery and engineering platform to create potent monoclonal antibodies for prevention and treatment of infectious diseases. The company emphasizes cutting-edge research, viral surveillance, and adaptive solutions to address emerging health challenges globally.Explore more
Invivyd Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Invivyd your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Invivyd is spiking on competitors!
Click to see if Invivyd had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Invivyd, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Invivyd launches new products
Funding: Get notified immidiatlly once Invivyd has new funding data
Congratulate Masked Content for being promoted to Masked Content at Invivyd
Check if Invivyd has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Invivyd recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Invivyd
Compare insights from companies similar to Invivyd, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Invivyd is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Invivyd is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Invivyd.
Invivyd financials insights
Gather financial insights about Invivyd, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$50M
Series B
$80M
2021
Series C
$336M
Share Placement
$309.4M
Invivyd Tech Stack
A closer look at the technologies used by Invivyd
Most Recent Scoops
Project
Invivyd has upsized the DECLARATION trial by approximately 500 subjects following a pre-specified blinded sample size re-estimation, creating an incremental cohort time-shifted into the summer period to capture additional COVID events.
Clinical Operations
Project
Invivyd has reported that PEMGARDA, its Emergency Use Authorization-approved COVID-19 monoclonal antibody for moderately to severely immunocompromised persons, has demonstrated durable, variant-stable protection and serves as proof of concept for the company's antibody platform. The product has generated revenues in the range of $50 million to $60 million, growing at approximately 20% or more.
Proof of Concept (POC), Pharmaceuticals
Project
Invivyd is conducting the DECLARATION Phase III pivotal trial evaluating VYD2311 across three arms placebo, single dose, and repeat monthly dosing with a primary endpoint of reduction in symptomatic PCR-positive COVID-19. Based on prior placebo-controlled randomized controlled trial experience with similar antibodies, the expected efficacy range is approximately 70% to 90% risk reduction relative to placebo.
Medical Research, Clinical Operations
Project
Invivyd has announced an upsizing of the DECLARATION trial, triggered in early April by an inbuilt algorithm designed to capture sufficient disease events given the cyclical nature of COVID-19 infection waves, with pivotal data readout targeted for late third quarter. At the time of the upsizing announcement, a meaningful number of efficacy events had already been accumulated.
Clinical Operations
Project
Pharmaceuticals, Clinical Operations
Invivyd News & Media
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
NEW HAVEN, Conn., June 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced enrollment of participants in its Phase 3 LIBERTY clinical trial is complete. The trial is comparing the safety and tolerability of the company’s investigational COVID-19 monoclonal antibody VYD2311 with an mRNA COVID-19 vaccine. The trial is also evaluating the safety and immune response when both are given together. VYD2311 is being developed as an alternative to vaccines for preventing COVID-19.Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
NEW HAVEN, Conn., June 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the first participants have been dosed in the LIBERTY Phase 3 clinical trial, a randomized, double-blind study that is evaluating the safety and tolerability and immunology of VYD2311 alone, an mRNA COVID-19 vaccine alone, and VYD2311 co-administered with a COVID-19 vaccine in healthy adults. VYD2311 is Invivyd’s vaccine-alternative monoclonal antibody (mAb) investigational candidate for the preInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Invivyd
Sign Up For FreeTo access detailed company insights
Invivyd, Inc. is a biopharmaceutical company focused on developing innovative antibody-based therapies to protect against evolving viral threats. It uses a proprietary discovery and engineering platform to create potent monoclonal antibodies for prevention and treatment of infectious diseases. The company emphasizes cutting-edge research, viral sur... Read More
